CDT’s main strengths are its recent operational transformation and evidence of a commercially attractive product or portfolio. Revenue has moved from zero to very substantial levels, profitability has turned positive with healthy margins, and cash flow has swung from burn to surplus, enabling both reinvestment and the initiation of dividends. The company is also investing heavily in R&D and capital projects, suggesting a strategic focus on building long‑term capabilities rather than simply harvesting near‑term gains.

Counterbalancing those positives are significant financial and strategic risks. The balance sheet has shown negative equity, thin liquidity, and rising debt, with a heavy reliance on goodwill and intangibles from recent acquisitions. The business appears to be heavily dependent on a relatively short operating history at scale, likely centered on a limited number of products, in a sector known for binary outcomes and intense competition. Stock splits and past cash burn highlight historical volatility, and it remains unclear how resilient the new revenue and cash flow levels will be under competitive or regulatory pressure.

The forward picture for CDT is one of high potential and high uncertainty. If the 2025 performance proves sustainable, and if management uses the new cash generation to repair the balance sheet, integrate acquisitions, and advance a diversified pipeline, the company could evolve into a more stable, mid‑size biotech with a stronger financial footing. Conversely, setbacks in its key products, difficulties digesting acquisitions, or renewed liquidity pressure could quickly erode the recent gains. Observers may want to watch for consistency in revenue, margins, cash flow, and balance sheet strengthening over the next few years to better gauge the durability of this apparent inflection point.